Dcf Advisers, LLC Equillium, Inc. Transaction History

Dcf Advisers, LLC

$177 Million
Q4 2024

A detailed history of Dcf Advisers, LLC transactions in Equillium, Inc. stock. As of the latest transaction made, Dcf Advisers, LLC holds 62,947 shares of EQ stock, worth $59,170. This represents 0.03% of its overall portfolio holdings.

Number of Shares

62,947

Previous 32,962 90.97%

Holding current value

$59,170

Previous $27,000 81.48%

% of portfolio

0.03%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 11, 2025	BUY	$0.6 - $1.38 $17,991 - $41,379	29,985 Added 90.97%	62,947 $49,000
Q2 2024 Aug 12, 2024	BUY	$0.66 - $2.33 $21,754 - $76,801	32,962 New	32,962 $22,000
Q3 2023 Nov 13, 2023	SELL	$0.72 - $0.9 $30,061 - $37,576	-41,752 Reduced 37.4%	69,871 $51,000
Q2 2023 Aug 09, 2023	SELL	$0.49 - $0.79 $22,246 - $35,866	-45,400 Reduced 28.91%	111,623 $83,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.24 $50,701 - $112,268	-90,539 Reduced 36.57%	157,023 $114,000
Q4 2022 Feb 13, 2023	BUY	$0.83 - $2.26 $11,424 - $31,106	13,764 Added 5.89%	247,562 $262,000
Q3 2022 Nov 14, 2022	BUY	$1.93 - $3.14 $231,158 - $376,080	119,771 Added 105.04%	233,798 $519,000
Q2 2022 Aug 11, 2022	SELL	$1.69 - $3.26 $87,264 - $168,333	-51,636 Reduced 31.17%	114,027 $233,000
Q1 2022 May 13, 2022	SELL	$2.99 - $4.19 $65,788 - $92,192	-22,003 Reduced 11.72%	165,663 $522,000
Q4 2021 Feb 10, 2022	BUY	$3.77 - $6.99 $7,540 - $13,980	2,000 Added 1.08%	187,666 $708,000
Q3 2021 Nov 15, 2021	BUY	$4.84 - $6.91 $523,339 - $747,164	108,128 Added 139.45%	185,666 $1.27 Million
Q2 2021 Aug 13, 2021	BUY	$5.11 - $7.64 $396,219 - $592,390	77,538 New	77,538 $457,000

Others Institutions Holding EQ

# of Institutions

Shares Held

11.3M

Call Options Held

Put Options Held

View Full List

About Equillium, Inc.

Ticker EQ
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,352,100
Market Cap $32.3M
Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...

More about EQ

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dcf Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dcf Advisers, LLC with notifications on news.

Account